From: The impact of polymorphisms in STAT6 on treatment outcome in HCV infected Taiwanese Chinese
Haplotypes* | SVR (+) (%) | SVR (−) (%) | P Global† | P individual§ | OR (95% CI) |
---|---|---|---|---|---|
AGGT | 66 (20.3) | 40 (19.6) | 0.2126 | 0.8583 | 1.04 (0.67, 1.61) |
AGGC | 4 (1.2) | 2 (1.0) | 0.7940 | 1.25 (0.23, 6.91) | |
AGAT | 2 (0.6) | 3 (1.5) | 0.3206 | 0.41 (0.07, 2.50) | |
AGAC | 144 (44.2) | 87 (42.6) | 0.7305 | 1.06 (0.75, 1.51) | |
AAGC | 78 (23.9) | 63 (30.9) | 0.0778 | 0.70 (0.48, 1.04) | |
GGGC | 31 (9.5) | 9 (4.4) | 0.0306* | 2.28 (1.06, 4.89) | |
GGAC | 1 (0.3) | 0 (0.0) | 0.4285 | - |